Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mastercard

Thermo Fisher Scientific

The S&P 500 saw its trailing 12-month real earnings per share (EPS) grow by approximately 1.4% on average every year over the past five years. The index's share price ($3,629.65 as of Wednesday) rose by nearly 74% over the past five years through Nov. 25.

This Trio Is Growing Earnings Fast

Medtronic PLC's (MDT) CEO Geoffrey Martha on Q2 2021 Results - Earnings Call Transcript

Deferred procedures due to the pandemic impact Medtronic's (MDT) Q2 performance.

Medtronic's (MDT) Q2 Earnings Beat Estimates, Margins Fall

Shares of Medtronic (NYSE:MDT) rose 0.2% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 22.14% over the past year to $1.02, which beat the estimate of $0.80.

Medtronic: Q2 Earnings Insights

Medtronic (MDT) delivered earnings and revenue surprises of 30.77% and 8.51%, respectively, for the quarter ended October 2020. Do the numbers hold clues to what lies ahead for the stock?

Medtronic (MDT) Tops Q2 Earnings and Revenue Estimates

Medtronic earnings and sales beat fiscal Q2 estimates. Shares of the medical products giant rose slightly, near a prior buy point.

Medtronic Earnings Top; MDT Stock Near Buy Point

- Q2 Revenue of $7.6 Billion Decreased 0.8% Reported and 1.5% Organic - Q2 GAAP Diluted EPS of $0.36; Q2 Non-GAAP Diluted EPS of $1.02 DUBLIN, Nov. 24, 2020 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced financial results for its second quarter of fiscal year 2021, which ended...

Medtronic Reports Second Quarter Fiscal 2021 Financial Results

Medtronic is scheduled to report its fiscal Q2 2021 results on Tuesday, November 24. We expect Medtronic to likely beat the revenue and earnings expectations, driven by improved demand for medical devices with an increase in the number of procedures performed sequentially.

Earnings Beat On The Cards For Medtronic?

Medtronic (MDT) is hopeful about a sequential improvement of about 8% in the fiscal second quarter, which implies a 9% year-over-year decline.

Will Medtronic (MDT) Report Volume Improvement in Q2 Earnings?

DexCom

ABIOMED

Biotech stocks simply can't match these reliable returns.

These 3 Medical Device Stocks Leave Biotech in the Dust

Medtronic (MDT) expects Medicrea's capabilities and solutions to complement its fully-integrated procedural solution for surgical planning and delivery.

Medtronic's (MDT) Medicrea Buyout to Aid AI Spinal Surgery Line

DUBLIN, Nov. 16, 2020 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that the primary results of the Medtronic-sponsored STOP AF First clinical trial have been published in the New England Journal of Medicine (NEJM). Results from the...

The New England Journal of Medicine: Medtronic Cryoablation is a Superior Treatment Option for Symptomatic Paroxysmal Atrial Fibrillation Compared to Drug Therapy

DUBLIN, Nov. 16, 2020 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that it has completed its friendly tender offer for France-based Medicrea International (Euronext Growth Paris: FR0004178572 – ALMED Medicrea; OTCQX Best Market –...

Medtronic Completes Acquisition of Medicrea

DUBLIN, Nov. 13, 2020 /PRNewswire/ -- Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced that it has been recognized as one of the world's leading companies for sustainability with its inclusion in the Dow Jones Sustainability North America Index (DJSI...

Medtronic Ranked as a Leading Sustainability Company

Medtronic's (MDT) strategic acquisition of Companion Medical strengthens the company's data science and AI capabilities.

Medtronic (MDT) Integrates InPen With Guardian Connect

Medtronic is a Dividend Champion with 43 consecutive years of dividend growth.  Shares currently yield 2.24%. Medtronic is a leader in the med-tech space with over 70 years of expertise in pushing the healthcare sector forward.

Medtronic: Double-Digit Return Potential Is In Sight

Extra Space Storage

Freeport-McMoRan

Alphabet

Jazz Pharmaceuticals

Eli Lilly

Parker-Hannifin

Royal Caribbean Cruises

Waters

Walmart

It is almost hard to believe, in what has been one of the most unbelievable years in recent history, that Halloween is this weekend and Thanksgiving is right around the corner.

BofA Securities Top 10 US Stock Ideas for the Rest of 2021

DUBLIN, Oct. 26, 2020 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval for the Abre™ venous self-expanding stent system. This device is indicated for use in the iliofemoral...

Medtronic Venous Stent Receives U.S. FDA Approval to Treat Venous Outflow Obstruction

Titan Medical Inc

TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announced today that it has completed the first technical milestone under the development and license agreement with Medtronic plc (“Medtronic”) (NYSE: MDT), and is due to receive a U.S. $10 million payment. The development and license agreement provides for the development of

Titan Medical Announces Achievement of $10 Million Technical Milestone Under Medtronic Development and License Agreement

DUBLIN, Oct. 20, 2020 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced statistically significant 12-month results from a large, multicenter randomized controlled trial (RCT) that further validate the superiority of DTM™ Spinal Cord...

Patients Report Superior, Sustained and Profound Back Pain Relief at 12 Months with DTM™ Spinal Cord Stimulation Therapy Using the Medtronic Intellis™ Platform

Feasibility Study of Medtronic Drug-Coated Balloon Technology for Challenging Below-the-Knee Disease Shows Promise in Patients with Critical Limb Ischemia DUBLIN, Oct. 18, 2020 /PRNewswire/ -- Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced the...

Nine-Month Results from Medtronic IN.PACT BTK Study Presented in Late-Breaking Clinical Trial Sessions at TCT Connect Annual Meeting

Colgate-Palmolive

Costco

General Dynamics

Johnson & Johnson

Lockheed Martin

Merck

PepsiCo

Procter & Gamble

10 Dividend Growth Stocks For October 2020

Half Moon Medical's Technology Now Ready for Evaluation in Early Feasibility Study DUBLIN, Oct. 14, 2020 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced a partnership with The Foundry – a medical device company incubator – dating back to...

Medtronic Announces Partnership with The Foundry to Develop Innovative Mitral Valve Repair Technology

DUBLIN, Oct. 14, 2020 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, has been named one of America's most JUST companies, ranking 29th overall on the 'Forbes JUST 100' list for 2021 and first in its industry category of Healthcare Equipment and Services....

Medtronic Named One of America's Most JUST Companies by Forbes and JUST Capital

Medtronic Also Begins Feasibility Study of Evolut TAVR System in Moderate and Asymptomatic Aortic Stenosis Patients DUBLIN, Oct. 14, 2020 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in structural heart therapies, today announced it will begin a randomized, head-to-head study...

News for Medtronic Stock (MDT)